Assertio Therapeutics, Inc Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Revenues:
Royalties
Product sales, net
Commercialization agreement, net
Royalties and milestones
Total revenues
Costs and expenses:
Cost of sales (excluding amortization of intangible assets)
Research and development expenses
Acquired in-process research and development
Selling, general and administrative expenses
Amortization of intangible assets
Loss on impairment of intangible asset
Restructuring charges
Total costs and expenses
(Loss) income from operations
Other income (expense):
Litigation settlement
Gain on debt extinguishment
Other income, net
Interest expense
Gain on divestiture of Lazanda
Loss on prepayment of Senior Notes
Senior Notes
Total loss on prepayment of Senior Notes
Total other expense
Net (loss) income before income taxes
Income tax benefit (expense)
Net (loss) income
Unrealized gain on available-for-sale securities, net of tax
Other comprehensive income:
Unrealized gain on available-for-sale securities, net of tax
Comprehensive (loss) income
Basic net (loss) income per share (in dollars per share)
Diluted net (loss) income per share (in dollars per share)
Shares used in computing basic net (loss) income per share (in shares)
Shares used in computing diluted net (loss) income per share (in shares)

Comments